Positron emission tomography in the management of patients with indolent non-Hodgkin's lymphoma

Clinical Lymphoma

Volumn 4, Issue 1, 2003, Pages 50-51

  Naumann, Ralph ^a   Beuthien Baumann, Bettina ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; DIAGNOSTIC ACCURACY; FOLLICULAR LYMPHOMA; HUMAN; INTERMETHOD COMPARISON; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; T CELL LYMPHOMA;

EID: 0038353696     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9655(11)70009-4     Document Type: Note

References (15)

1. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-Fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2001; 81:20-25.
2. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793-800.
3. Jerusalem G, Beguin Y. Positron emission tomography in Non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 2002; 3:56-61.
4. Kostakoglu L, Goldsmith SJ. 18F-FDG PET Evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003; 44:224-239.
5. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32:1211-1218.
6. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190:111-116.
7. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
8. Stumpe KD, Urbinelli M, Steinert HC, et al. Wholebody positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25:721-728.
9. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91:889-899.
10. Blum RH, Seymour JF, Wirth A, et al. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4:43-49.
11. Najjar F, Hustinx R, Jerusalem G, et al. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm 2001; 16:297-304.
12. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12:825-830.
13. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma WHO Classification. Blood 2003; 101:3875-3876,
14. Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer Press; 2001.
15. Hoffmann K, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185-1189.